387 related articles for article (PubMed ID: 27261451)
1. Personalized medicine in cystic fibrosis: genistein supplementation as a treatment option for patients with a rare S1045Y-CFTR mutation.
Arora K; Yarlagadda S; Zhang W; Moon C; Bouquet E; Srinivasan S; Li C; Stokes DC; Naren AP
Am J Physiol Lung Cell Mol Physiol; 2016 Aug; 311(2):L364-74. PubMed ID: 27261451
[TBL] [Abstract][Full Text] [Related]
2. Activation of 3-phosphoinositide-dependent kinase 1 (PDK1) and serum- and glucocorticoid-induced protein kinase 1 (SGK1) by short-chain sphingolipid C4-ceramide rescues the trafficking defect of ΔF508-cystic fibrosis transmembrane conductance regulator (ΔF508-CFTR).
Caohuy H; Yang Q; Eudy Y; Ha TA; Xu AE; Glover M; Frizzell RA; Jozwik C; Pollard HB
J Biol Chem; 2014 Dec; 289(52):35953-68. PubMed ID: 25384981
[TBL] [Abstract][Full Text] [Related]
3. Measurements of Functional Responses in Human Primary Lung Cells as a Basis for Personalized Therapy for Cystic Fibrosis.
Awatade NT; Uliyakina I; Farinha CM; Clarke LA; Mendes K; Solé A; Pastor J; Ramos MM; Amaral MD
EBioMedicine; 2015; 2(2):147-53. PubMed ID: 26137539
[TBL] [Abstract][Full Text] [Related]
4. Defective function of the cystic fibrosis-causing missense mutation G551D is recovered by genistein.
Illek B; Zhang L; Lewis NC; Moss RB; Dong JY; Fischer H
Am J Physiol; 1999 Oct; 277(4):C833-9. PubMed ID: 10516113
[TBL] [Abstract][Full Text] [Related]
5. Personalized medicine in CF: from modulator development to therapy for cystic fibrosis patients with rare CFTR mutations.
Harutyunyan M; Huang Y; Mun KS; Yang F; Arora K; Naren AP
Am J Physiol Lung Cell Mol Physiol; 2018 Apr; 314(4):L529-L543. PubMed ID: 29351449
[TBL] [Abstract][Full Text] [Related]
6. Mechanism-Based Personalized Medicine for Cystic Fibrosis by Suppressing Pseudo Exon Inclusion.
Shibata S; Ajiro M; Hagiwara M
Cell Chem Biol; 2020 Dec; 27(12):1472-1482.e6. PubMed ID: 32905759
[TBL] [Abstract][Full Text] [Related]
7. The cystic fibrosis mutation G551D alters the non-Michaelis-Menten behavior of the cystic fibrosis transmembrane conductance regulator (CFTR) channel and abolishes the inhibitory Genistein binding site.
Derand R; Bulteau-Pignoux L; Becq F
J Biol Chem; 2002 Sep; 277(39):35999-6004. PubMed ID: 12124395
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological induction of CFTR function in patients with cystic fibrosis: mutation-specific therapy.
Kerem E
Pediatr Pulmonol; 2005 Sep; 40(3):183-96. PubMed ID: 15880796
[TBL] [Abstract][Full Text] [Related]
9. Mutation specific therapy in CF.
Kerem E
Paediatr Respir Rev; 2006; 7 Suppl 1():S166-9. PubMed ID: 16798551
[TBL] [Abstract][Full Text] [Related]
10. Lumacaftor and ivacaftor in the management of patients with cystic fibrosis: current evidence and future prospects.
Kuk K; Taylor-Cousar JL
Ther Adv Respir Dis; 2015 Dec; 9(6):313-26. PubMed ID: 26416827
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological Correction of Cystic Fibrosis: Molecular Mechanisms at the Plasma Membrane to Augment Mutant CFTR Function.
Arora K; Naren AP
Curr Drug Targets; 2016; 17(11):1275-81. PubMed ID: 26648081
[TBL] [Abstract][Full Text] [Related]
12. The cystic fibrosis mutation G1349D within the signature motif LSHGH of NBD2 abolishes the activation of CFTR chloride channels by genistein.
Melin P; Thoreau V; Norez C; Bilan F; Kitzis A; Becq F
Biochem Pharmacol; 2004 Jun; 67(12):2187-96. PubMed ID: 15163550
[TBL] [Abstract][Full Text] [Related]
13. Novel personalized therapies for cystic fibrosis: treating the basic defect in all patients.
Amaral MD
J Intern Med; 2015 Feb; 277(2):155-166. PubMed ID: 25266997
[TBL] [Abstract][Full Text] [Related]
14. A novel natural product compound enhances cAMP-regulated chloride conductance of cells expressing CFTR[delta]F508.
deCarvalho AC; Ndi CP; Tsopmo A; Tane P; Ayafor J; Connolly JD; Teem JL
Mol Med; 2002 Feb; 8(2):75-87. PubMed ID: 12080183
[TBL] [Abstract][Full Text] [Related]
15. Genetics of Cystic Fibrosis: Clinical Implications.
Egan ME
Clin Chest Med; 2016 Mar; 37(1):9-16. PubMed ID: 26857764
[TBL] [Abstract][Full Text] [Related]
16. Structural mechanisms for defective CFTR gating caused by the Q1412X mutation, a severe Class VI pathogenic mutation in cystic fibrosis.
Yeh JT; Yu YC; Hwang TC
J Physiol; 2019 Jan; 597(2):543-560. PubMed ID: 30408177
[TBL] [Abstract][Full Text] [Related]
17. Clinical implications of cystic fibrosis transmembrane conductance regulator mutations.
Mickle JE; Cutting GR
Clin Chest Med; 1998 Sep; 19(3):443-58, v. PubMed ID: 9759548
[TBL] [Abstract][Full Text] [Related]
18. Unravelling the Regions of Mutant F508del-CFTR More Susceptible to the Action of Four Cystic Fibrosis Correctors.
Amico G; Brandas C; Moran O; Baroni D
Int J Mol Sci; 2019 Nov; 20(21):. PubMed ID: 31683989
[TBL] [Abstract][Full Text] [Related]
19. Activation of deltaF508 CFTR in a cystic fibrosis respiratory epithelial cell line by 4-phenylbutyrate, genistein and CPX.
Andersson C; Roomans GM
Eur Respir J; 2000 May; 15(5):937-41. PubMed ID: 10853862
[TBL] [Abstract][Full Text] [Related]
20. Lumacaftor/ivacaftor combination for cystic fibrosis patients homozygous for Phe508del-CFTR.
Zhang W; Zhang X; Zhang YH; Strokes DC; Naren AP
Drugs Today (Barc); 2016 Apr; 52(4):229-37. PubMed ID: 27252987
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
